AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) major shareholder Peter W. Sonsini acquired 24,500 shares of the stock in a transaction dated Wednesday, November 28th. The stock was bought at an average price of $1.99 per share, for a total transaction of $48,755.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
AVEO opened at $2.07 on Monday. AVEO Pharmaceuticals, Inc. has a fifty-two week low of $1.49 and a fifty-two week high of $3.59. The firm has a market cap of $259.47 million, a price-to-earnings ratio of -12.94 and a beta of 1.98.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $2.47 million for the quarter, compared to analyst estimates of $0.68 million. Equities analysts forecast that AVEO Pharmaceuticals, Inc. will post -0.23 EPS for the current fiscal year.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Monday, November 12th. National Securities downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 6th. HC Wainwright set a $9.00 price objective on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, BidaskClub downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 19th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. AVEO Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $5.42.
WARNING: “Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Purchases 24,500 Shares of Stock” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/12/03/insider-buying-aveo-pharmaceuticals-inc-aveo-major-shareholder-purchases-24500-shares-of-stock.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Recommended Story: Bear Market
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.